---
title: 'Morning Brief — Friday, November 20, 2026'
type: 'episode'
url: 'https://doc.social/episodes/morning-brief-2026-11-20'
show: 'doc social Morning Brief'
show_url: 'https://doc.social/podcasts/morning-brief'
published: '2026-11-20'
audio: 'https://media.doc.social/podcasts/morning-brief/2026-11-20.mp3'
---

# Morning Brief — Friday, November 20, 2026

WEDI's fourth CMS-0057-F readiness survey (fielded Sept/Oct 2026, 174 responses; posted Nov 16): 10% of payers report the Prior Authorization API complete ahead of the January 1, 2027 compliance date (3% in Feb 2026); 25% at 75%, 37% at 50%, 7% at 25%, 20% at 0%/unsure; a majority say costs are running above expectations; providers 7% complete, 21% at 0%; CY 2027 PFS final rule makes the MIPS…

## Summary

4 stories this morning, for surgeons and the people who support them.

- **WEDI's fourth CMS-0057-F readiness survey (fielded Sept/Oct 2026, 174 responses; posted Nov 16): 10% of payers report the Prior Authorization API complete ahead of the January 1, 2027 compliance date (3% in Feb 2026); 25% at 75%, 37% at 50%, 7% at 25%, 20% at 0%/unsure; a majority say costs are running above expectations; providers 7% complete, 21% at 0%; CY 2027 PFS final rule makes the MIPS Electronic Prior Authorization measure optional (10 bonus points) for 2027 and required from 2028** — WEDI Interoperability and Prior Authorization Survey results deck (linked from the WEDI page; figures read from the slides): surveys Jan/Feb 2025 (243), Oct 2025 (173), Feb 2026 (83), Sept/Oct 2026 (174) of payers, providers, clearinghouses and health IT vendors; WEDI describes itself as an HHS advisor. Payer Prior Authorization API completion, Oct 2026: 100% 10%, 75% 25%, 50% 37%, 25% 7%, 0%/unsure 20% (Feb 2026: 3%, 10%, 35%, 39%, 13%). Top payer challenge Oct 2026: delegated third parties facing challenges connecting with different systems. Cost chart: majority 'more' than expected, no 'less' slice (Healthcare Dive, Nov 18, reports 62%: https://www.healthcaredive.com/news/few-payers-are-ready-for-looming-electronic-prior-authorization-deadline/874879/). Providers, Oct 2026: 100% 7%, 75%/50%/25% 14% each, 0% 21%, unsure 3%; 71% say it is very or extremely important that most contracted payers support the API. Rule facts from the CMS fact sheet for CMS-0057-F (https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f): impacted payers are MA organizations, state Medicaid and CHIP FFS programs, Medicaid managed care plans, CHIP managed care entities and QHP issuers on the FFEs; decisions within 72 hours (expedited) and seven calendar days (standard), excluding QHP issuers, from 2026; API requirements generally from January 1, 2027; drugs excluded. MIPS: CY 2027 PFS final rule (FR Doc. 2026-22743, 91 FR, published Nov 9, 2026) finalizes the Electronic Prior Authorization measure as 'an optional measure worth 10 bonus points under the MIPS Promoting Interoperability performance category for the CY 2027 performance period/2029 MIPS payment year' and required beginning with the CY 2028 performance period. The API deadline and this survey were not previously covered. [Source](https://www.wedi.org/2026/11/16/wedi-interoperability-and-prior-authorization-survey-results-2025-2026/)

- **Fziomed announces FDA 510(k) clearance of Dynavisc Tendon Protector (K262343, cleared Oct 28, 2026; announced Nov 18): absorbable carboxymethylcellulose/polyethylene oxide gel for management and protection of longitudinal tendon injuries; predicate Alafair Biosciences' VersaCoat Tendon Protector (K251655, July 2025); no clinical testing required** — Fziomed release, Nov 18, 2026: fully synthetic, ready-to-use absorbable gel applied after tendon repair; commercially available internationally for more than a decade, more than 50,000 patients. FDA letter and 510(k) summary (https://www.accessdata.fda.gov/cdrh_docs/pdf26/K262343.pdf): decision October 28, 2026; 21 CFR 878.3300, product code OWW, class II; sodium CMC and PEO gel in a capped syringe; indicated for 'the management and protection of longitudinal tendon injuries in which there has been no substantial loss of tendon tissue', may also be used on surrounding ligament and skeletal muscle; 'does not provide mechanical support and has not been evaluated in repair of transverse tears or injuries'; predicate VersaCoat Tendon Protector K251655 (openFDA: Alafair Biosciences, decision 2025-07-18); differences are implant material and the predicate's need for rehydration prior to use; bench, biocompatibility and a rabbit calcaneal tendon injury model; clinical testing not required. openFDA also lists Fziomed's Oxiplex De Novo DEN240038, decision 2025-06-17. Not previously covered. [Source](https://www.prnewswire.com/news-releases/fziomed-announces-fda-510k-clearance-for-dynavisc-tendon-protector-in-the-united-states-302942783.html)

- **J Arthroplasty (University of Kentucky/Liberty University/OrthoVirginia, online Nov 18): in 435,789 unilateral primary TKAs (2021-2023), factor Xa inhibitors were associated with more 90-day manipulation under anesthesia than aspirin (3.9% vs 2.8%; adjusted OR 1.60, 95% CI 1.54-1.67); rivaroxaban vs apixaban 3.7% vs 3.9% unadjusted (P=0.11), adjusted OR 0.89 (0.83-0.95)** — McGee AS, et al. Xa Inhibitors Are Associated with an Increased Risk of Manipulation after Primary Total Knee Arthroplasty Compared to Aspirin in a Contemporary Cohort. J Arthroplasty, online Nov 18, 2026, doi 10.1016/j.arth.2026.11.072. Database cohort; perioperative window 30 days before to 3 days after surgery: rivaroxaban 32,778 (7.5%), apixaban 53,504 (12.3%), aspirin 349,507 (80.2%). MUA by CPT 27570 within 90 days: 13,142 (3.0%) overall. Logistic regression adjusted for demographics, Elixhauser Comorbidity Index and BMI. Not randomized. PEPPER (NEJM) was covered in the 2026-11-12 episode; this paper was not previously covered. [Source](https://pubmed.ncbi.nlm.nih.gov/43051503/)

- **Global Spine J (Jefferson/Rothman, online Nov 18): TriNetX propensity-matched study (1,193 per cohort): cervical epidural steroid injection within 3 months before ACDF associated with more coded pseudarthrosis (13.33% vs 8.72%; RR 1.53, 95% CI 1.21-1.93), new-onset cervicalgia (35.42% vs 23.52%) and 5-year cervical reoperation (3.86% vs 2.18%; RR 1.77, 1.10-2.84); no significant differences for injections 3-6 months, 6-12 months or more than 1 year before surgery** — Pignataro J, et al. Preoperative Cervical Epidural Steroid Injection Within Three Months of ACDF Is Associated with Increased Long-Term Pseudoarthrosis and Reoperation Rates: A Propensity Matched Retrospective Analysis. Global Spine J, online Nov 18, 2026, doi 10.1177/21925682261511575. Retrospective cohort, TriNetX; 1:1 propensity score matching for demographics and comorbidities; primary outcome a coded diagnosis of pseudarthrosis after fusion or arthrodesis; secondary outcomes new-onset cervicalgia, new-onset cervical disc displacement, surgical site infection and all-cause coded cervical reoperation. The abstract does not state that number of levels was matched. Not previously covered. [Source](https://pubmed.ncbi.nlm.nih.gov/43050702/)

### Contribute to the Brief

Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio).

Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it.

_Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._
